Nivolumab plus ipilimumab improves survival results in MSI-H/dMMR metastatic colorectal cancer

Dr Elena Elez speaks to ecancer about the health-related quality of life analyses from CheckMate 8HW.

This clinical trial explores nivolumab plus ipilimumab versus nivolumab monotherapy for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC).

Results show that the combination therapy significantly improves progression-free survival and enhances patients' quality of life, despite potential increased toxicity.

Dr Elez says that these findings underscore the effectiveness of immunotherapy in improving patient outcomes.